Lck inhibitor II

• CAT Number: I030587
• CAS Number: 918870-43-6
• Molecular Formula: C24H26N6O3
• Molecular Weight: 446.51
• Purity: 98%
• Synonyms: Lck inhibitor II; 3-(2-(1H-Benzo[d]imidazol-1-yl)-6-(2-morpholinoethoxy)-pyrimidin-4-ylamino)-4-methylphenol.
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 3-(2-(1H-Benzo[d]imidazol-1-yl)-6-(2-morpholinoethoxy)-pyrimidin-4-ylamino)-4-methylphenol
• InChI: InChI=1S/C24H26N6O3/c1-17-6-7-18(31)14-20(17)26-22-15-23(33-13-10-29-8-11-32-12-9-29)28-24(27-22)30-16-25-19-4-2-3-5-21(19)30/h2-7,14-16,31H,8-13H2,1H3,(H,26,27,28)
• InChIKey: DKDNLOIZODSWFH-UHFFFAOYSA-N
• SMILES: OC1=CC=C(C)C(NC2=NC(N3C=NC4=CC=CC=C34)=NC(OCCN5CCOCC5)=C2)=C1

Lck Inhibitor II(CAT: I030587) is a potent and selective inhibitor of lymphocyte-specific protein tyrosine kinase (Lck), a key component of T-cell receptor (TCR) signaling. By targeting Lck, this compound disrupts downstream signaling pathways critical for T-cell activation, proliferation, and cytokine production. Lck Inhibitor II is widely used in immunology and oncology research to study T-cell-mediated immune responses, autoimmune disorders, and the tumor microenvironment. Its specificity makes it an essential tool for investigating Lck’s role in T-cell activation and developing targeted therapies for immune-related diseases and certain cancers, such as T-cell lymphomas.